Home | Sitemap | Search | Contact A- A A+
   
 
    Public Member Support us  
 

IBCSG 18-98 / BIG 1-98 

Adjuvant therapy for postmenopausal patients with operable breast cancer who have estrogen receptor or progesteron receptor positive tumor.

Tamoxifen vs. letrozole vs. tamoxifen followed by letrozole vs. letrozole followed by tamoxifen

DESIGN

Design Trial 18-98

Results & Publications


Presentations


Publications

Study Chair
Prof. Beat Thürlimann - St. Gallen, Switzerland

Statisticians
Anita Giobbie-Hurder
Zhuoxin Sun


Trial Coordinators
Holly Shaw, Adrianna Cesario

Data Managers
Susan Fischer, Dawn Weinbaum,

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 836 6097
Email: ibcsg18_BIG1-98@fstrf.org

Date of Activation
March, 1998

Date of Closure
Core Protocol: May 13, 2003
GS/SLP Substudy: February 7, 2003
BMD Substudy: February 7, 2003
New Bone Substudy: January 31, 2007
Fingernail Pilot Substudy: July 31, 2007
Cognitive Function Substudy: May 20, 2008

Final Accrual
Core Protocol: 8028 patients
GS/SLP Substudy: 65 patients
BMD Substudy: 39 patients
New Bone Substudy: 458 patients
Fingernail Pilot Substudy: 16 patients
Cognitive Function Substudy: 135 patients


Results Publications Results & Publications
Other Pathology


News

18.12.2014:
New publications are available 

11.12.2014:
San Antonio Breast Cancer Symposium 2014: IBCSG Presents SOFT Results.

10.12.2014:
IBCSG and Merck Announce Opening of International PANACEA Study of Patients with HER2+ Breast

All News

 
  Print